Leucine-rich glioma-inactivated 1 (LGI1)

Leucine-rich glioma-inactivated 1 (LGI1) is a secreted neuronal protein, notable for its leucine-rich repeats and epilepsy-associated epitempin family domains. Unlike classical therapeutic targets such as receptors or enzymes, LGI1 is not a cell-surface receptor nor an ion channel, but rather influences synaptic function by interacting with partners like ADAM22/ADAM23 to regulate synapse stabilization and neuronal excitability. Pathogenic variants in LGI1 cause autosomal dominant lateral temporal lobe epilepsy, and autoantibodies directed against LGI1 are implicated in autoimmune encephalitis, leading to seizures and other neurological symptoms. LGI1 is thus clinically significant as a biomarker and genetic risk locus, rather than as a direct therapeutic target. Note: LGI1 is distinct from DNA ligase 1 (LIG1), which is a DNA repair enzyme and IS a therapeutic target[1][3][5]. There is no evidence in the search results linking “leucine rich glioma inactivated 1” to receptor, enzyme, transporter, or other conventional therapeutic target classes. Detection of LGI1 autoantibodies is an important diagnostic tool for certain forms of encephalitis.

Other names

LGI1Epitempin-1Epilepsy, familial temporal lobe, 1 protein

Not applicable (not therapeutically targeted directly; disease involvement is via autoantibodies or genetic mutation)